

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/44174 A2

(51) International Patent Classification⁷: **C07D 417/04**,
A61K 31/427, A61P 35/00

(21) International Application Number: PCT/US01/45227

(22) International Filing Date:
30 November 2001 (30.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/251,213 1 December 2000 (01.12.2000) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB PHARMA COMPANY**
[US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **YUE, Eddy, W.**
[US/US]; 9 Altemus Drive, Landenberg, PA 19350-1357 (US).

(74) Agents: **PATEL, Rena et al.**; Bristol-Myers Squibb Company, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 3-(2,4-DIMETHYLTHIAZOL-5-YL) INDENO[1,2-C]PYRAZOL-4-ONE DERIVATIVES AND THEIR USE

(57) **Abstract:** The present invention relates to 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-ones of formula (1) which are potent inhibitors of cyclin dependent kinases. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.



WO 02/44174 A2

5

TITLE

3-(2,4-Dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one

Derivatives and Their Uses

FIELD OF THE INVENTION

This invention relates generally to novel 3-(2,4-Dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives which are useful as cyclin dependent kinase (cdk) inhibitors, pharmaceutical compositions comprising the same, methods for using the same for treating proliferative diseases, and intermediates and processes for making the same.

15

BACKGROUND OF THE INVENTION

One of the most important and fundamental processes in biology is the division of cells mediated by the cell cycle. This process ensures the controlled production of subsequent generations of cells with defined biological function. It is a highly regulated phenomenon and responds to a diverse set of cellular signals both within the cell and from external sources. A complex network of tumor promoting and suppressing gene products are key components of this cellular signaling process. Over expression of the tumor promoting components or the subsequent loss of the tumor suppressing products will lead to unregulated cellular proliferation and the generation of tumors (Pardee, Science 246:603-608, 1989).

20

25

30

35

Cyclin dependent kinases (cdks) play a key role in regulating the cell cycle machinery. These complexes consist of two components: a catalytic subunit (the kinase) and a regulatory subunit (the cyclin). To date, nine kinase subunits (cdk 1-9) have been identified along with several regulatory subunits (cyclins A-H). (A.M. Senderowicz and E.A. Sausville Journal of the National Cancer Institute (2000),

5 92 (5), 376-387; and S. Mani; C. Wang; K. Wu; R. Francis; R. Pestell *Exp. Opin. Invest. Drugs* (2000) 9(8), 1849-1870).

Each kinase associates with a specific regulatory partner and together make up the active catalytic moiety. Each transition of the cell cycle is regulated by a
10 particular cdk complex: G1/S by cdk2/cyclin E, cdk4/cyclin D1 and cdk6/cyclinD2; S/G2 by cdk2/cyclin A and cdk1/cyclin A; G2/M by cdk1/B. The coordinated activity of these kinases guides the individual cells through the replication process and ensures the vitality of each subsequent generation
15 (Sherr, *Cell* 73:1059-1065, 1993; Draetta, *Trends Biochem. Sci.* 15:378-382, 1990)

An increasing body of evidence has shown a link between tumor development and cdk related malfunctions. Over expression of the cyclin regulatory proteins and subsequent
20 kinase hyperactivity have been linked to several types of cancers (Jiang, *Proc. Natl. Acad. Sci. USA* 90:9026-9030, 1993; Wang, *Nature* 343:555-557, 1990). More recently, endogenous, highly specific protein inhibitors of cdks were found to have a major affect on cellular proliferation (Kamb
25 et al, *Science* 264:436-440, 1994; Beach, *Nature* 336:701-704, 1993). These inhibitors include p16^{INK4} (an inhibitor of cdk4/D1), p21^{CIP1} (a general cdk inhibitor), and p27^{KIP1} (a specific cdk2/E inhibitor). A recent crystal structure of p27 bound to cdk2/A revealed how these proteins effectively
30 inhibit the kinase activity through multiple interactions with the cdk complex (Pavletich, *Nature* 382:325-331, 1996). These proteins help to regulate the cell cycle through specific interactions with their corresponding cdk complexes. Cells deficient in these inhibitors are prone to
35 unregulated growth and tumor formation.

5 Protein kinases, in particular, CDK, play a role
in the regulation of cellular proliferation. Therefore, CDK
inhibitors could be useful in the treatment of cell
proliferative disorders such as cancer, familial
adenomatosis polyposis, neuro-fibromatosis, psoriasis,
10 fungal infections, endotoxic shock, trasplantaion rejection,
vascular smooth cell proliferation associated with
atherosclerosis, pulmonary fibrosis, arthritis
glomerulonephritis and post-surgical stenosis and restenosis
(U.S. Patent No. 6,114,365). CDKs are also known to play a
15 role in apoptosis.

Therefore CDK inhibitors, could be useful in the
treatment of useful of cancer; viral infections, for
example, herpevirus, poxvirus, Epstein-Barr virus, Sindbis
virus and adenovirus; prevention of AIDS development in HIV-
20 infected individuals; autoimmune diseases, for example,
systemic lupus, erythematosus, autoimmune mediated
glomerulonephritis, rheumatoid arthritis, psoriasis,
inflammatory bowel disease, and autoimmune diabetes
mellitus; neurodegenerative disorders, for example,
25 Alzheimer's disease, AIDS-related dementia, Parkinson's
disease, amyotrophic lateral sclerosis, retinitis
pigmentosa, spinal muscular atrophy and cerebellar
degeneration; myelodysplastic syndromes, aplastic anemia,
ischemic injury associated with myocardial infarctions,
30 stroke and reperfusion injury, arrhythmia, atherosclerosis,
toxin-induced or alcohol related liver diseases,
hematological diseases, for example, chronic anemia and
aplastic anemia; degenerative diseases of the
musculoskeletal system, for example, osteoporosis and
35 arthritis, aspirin-sensitive rhinosinusitis, cystic

5 fibrosis, multiple sclerosis, kidney diseases and cancer
pain (U.S. Patent No. 6,107,305).

It has also been discovered that some cyclin-dependent
kinase inhibitors can be used in combination therapy with
some other anticancer agents. For example, the cytotoxic
10 activity of the cyclin-dependent kinase inhibitor,
flavopiridol, has been used with other anticancer agents in
cancer combination therapy. Cancer Research, 57, 3375
(1997).


Also, it has recently been disclosed that CDK
15 inhibitors may be useful in the chemoprevention of cancer.
Chemoprevention is defined as inhibiting the development of
invasive cancer by either blocking the initiating mutagenic
event or by blocking the progression of pre-malignant cells
that have already suffered an insult or inhibiting tumor
20 relapse (U.S. Patent No. 6,107,305).

Furthermore, it has recently been discovered that cdk5
is involved in the phosphorylation of tau protein, and
therefore CDK inhibitors may be useful in the treatment of
Alzheimer's disease (J. Biochem., 117, 741-749, 1995).

25 This body of evidence has led to an intense search for
small molecule inhibitors of the cdk family as an approach
to cancer chemotherapy. There are no known examples of
molecules related to the current invention which describe 5-
substituted-indeno[1,2-c]pyrazoles as cdk inhibitors. There
30 is one case describing indeno[1,2-c]pyrazoles having
anticancer activity. There are two other examples which
describe indeno[1,2-c]pyrazoles having unrelated utilities
and structures.


A series of indeno[1,2-c]pyrazoles having anticancer
35 activity are described in JP 60130521 and JP 62099361 with
the following generic structure:

5




No substitution is claimed on the indenophenyl portion of the molecule and the molecules are not indicated to be cdk inhibitors. In addition, we discovered that substitution at the 5-position was critical for cdk inhibitory activity.

A series of indeno[1,2-c]pyrazoles having herbicidal activity are described in GB.2223946 with the following generic structure:



The above compounds differ from the presently claimed invention in X_n is defined as halo, alkyl, haloalkyl, and haloalkoxy; $n = 0-2$. In addition, R_1 is defined as acyl and R_2 is defined as alkyl or cycloalkyl.

A series of 1-(6'-substituted-4'-methylquinol-2'-yl)-3-methylindeno[1,2-c]pyrazoles having CNS activity are described by Quraishi, Farmaco 44:753-8, 1989 with the following generic structure:



5


Compounds of this series are not considered to be part of the presently claimed invention.

Furthermore, Nugiel et al, International Application
 10 Number WO 99/54308, published October 28, 1999, discloses a class of indeno[1,2-c]pyrazol-4-ones as cyclin dependent kinase (CDK) inhibitors for the potential treatment of cancer. Although, WO 99/54308 generally discloses indeno[1,2-c]pyrazol-4-one compounds, the compounds of this
 15 invention, or the unexpected activity of the compounds of this invention, are not specifically disclosed.

SUMMARY OF THE INVENTION

The present invention describes a class of 3-(2,4-Dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-ones or
 20 pharmaceutically acceptable salt forms thereof that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk 1-9 and their regulatory subunits known as cyclins A-H.

25 This invention is a class of 3-(2,4-Dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-ones which exhibit remarkable and unexpected improvements as cancer therapeutic agents compared to the compounds disclosed in WO 99/54308. The compounds of this invention are 3-(2,4-dimethylthiazol-5-yl)-5-(substituted carbamoylamino)indeno[1,2-c]pyrazol-4-ones which can be represented by formula I:
 30




wherein R is defined below or pharmaceutically acceptable salts thereof are cyclin dependent kinase inhibitors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The compounds of this invention all exhibited outstanding enzyme inhibitory activity. The most preferred compounds of this invention show excellent activity against tumor cells growing in culture; however, normal cells as represented by the fibroblast AG1523 are comparatively spared. The most preferred compounds of this invention have excellent inhibitory activity against CDK2/E which translates into good cellular activity in the HCT116 colon cancer cell line. In addition, these compounds show good selectivity for HCT116 tumor cells over normal fibroblast cells (AG1523).

[1] The present invention, in a first embodiment, describes novel compounds of formula (I):



or stereoisomers thereof, N-Oxides thereof, pharmaceutically acceptable salts thereof, and prodrugs thereof, wherein:

5 R is independently at each occurrence selected from the group: H, NR^1R^2 , $\text{NR}^1\text{C}(\text{O})\text{R}^3$, $\text{NR}^1\text{C}(\text{O})\text{OR}^5$, $\text{NHC}(\text{O})\text{NR}^1\text{R}^2$, $\text{NHC}(\text{S})\text{NR}^1\text{R}^2$, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with 0-4 R^4 substituents;

10 R^1 is selected from the group: H, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl;

R^2 is selected from the group: H, C1-4 alkyl, phenyl, and benzyl;

alternatively, R^1 and R^2 , together with the nitrogen
15 atom to which they are attached, form a 4-8 membered heterocycl group or a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocycl or heterocyclenyl group is substituted with 0-4 R^4 substituents;

20 R^3 is selected from the group: H, halo, -CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl; and

R^4 is selected from the group: halo, -CN, C1-4 haloalkyl, C1-4 alkyl, phenyl, and benzyl.

R^5 is selected from the group: H, C1-4 alkyl, phenyl,
25 and benzyl.

[2] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

R is a 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S; wherein the
30 heterocycle is substituted with 0-3 R^4 substituents.

[3] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

5 R is a 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with 0-2 R⁴ substituents.

[4] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

10 R is a 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with a R⁴ substituent.

[5] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

15 R is a 5-6 membered hetroaryl, heterocyclyl, or heterocyclenyl group, substituted with 0-3 R⁴ substituents.

[6] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

R is H or NR¹R²;

20 R¹ is selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl;

R² is selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl;

alternatively, R¹ and R², together with the nitrogen
25 atom to which they are attached, form a 4-8 membered heterocycl group or a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocycl or heterocyclenyl group is substituted with 0-3 R⁴ substituents; and

30 R⁴ is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

[7] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

R is H or NR¹R²;

5 R^1 is selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl; and

R^2 is selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl.

 [8] In a preferred embodiment, the present invention
10 provides a novel compound of embodiment [1], wherein:

 R is H or NR^1R^2 ;

R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocycl group containing an additional 0-1 N, S, or O atom, wherein the
15 heterocycl is substituted with 0-3 R^4 substituents; and

R^4 is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

 [9] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

20 R is H or NR^1R^2 ;

R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclyl is substituted with 0-2 R^4 substituents; and

25 R^4 is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

 [10] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

R^1 and R^2 , together with the nitrogen atom to which
30 they are attached, form a heterocyclyl group selected from the group consisting of pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl,

5 and piperazinyl, wherein the heterocyclyl is substituted with 0-3 R⁴ substituents; and

R⁴ is selected from the group: halo, -CN, C₁-4 haloalkyl, C₁-4 alkyl, phenyl, and benzyl.

[11] In a preferred embodiment, the present invention
10 provides a novel compound of embodiment [1], wherein:

R¹ and R², together with the nitrogen atom to which they are attached, form a heterocyclyl group selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl, wherein the heterocyclyl is substituted with 0-
15 3 R⁴ substituents; and

R⁴ is selected from the group: halo, -CN, C₁-4 haloalkyl, C₁-4 alkyl, phenyl, and benzyl.

[12] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

20 R is H or NR¹R²;

R¹ and R², together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclenyl is substituted with 0-3 R⁴ substituents; and

25 R⁴ is selected from the group: halo, -CN, C₁-4 haloalkyl, C₁-4 alkyl, phenyl, and benzyl.

[13] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

R is H or NR¹R²;

30 R¹ and R², together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclenyl is substituted with 0-2 R⁴ substituents; and

5 R^4 is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

[14] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

R is H or NR¹R²;

10 R¹ and R², together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group selected from the group consisting of: 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, 1,2,3,4-tetrahydrohydropyridine, 1,2-dihydropyridyl,
15 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridine, 1,4,5,6-tetrahydropyrimidine, wherein the heterocyclenyl is substituted with 0-2 R⁴ substituents; and

R^4 is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

20 [15] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

R^4 is selected from the group: C₁₋₄ haloalkyl, C₁₋₄ alkyl, and benzyl.

 [16] In a preferred embodiment, the present invention
25 provides a novel compound of embodiment [1], wherein:

R^4 is C₁₋₄ alkyl.

 [17] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

R^4 is methyl.

30 [18] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

 R is NR¹R²; and

5 R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclyl is substituted with a R^4 substituent.

10 [19] In a preferred embodiment, the present invention provides a novel compound of embodiment [1], wherein:

 R is NR^1R^2 ; and

15 R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclenyl is substituted with a R^4 substituent.

 [20] In a most preferred embodiment, the compounds of this invention are selected from:

 3-(2,4-dimethylthiazol-5-yl)-5-
(carbamoylamino)indeno[1,2-c]pyrazol-4-one;
20 3-(2,4-dimethylthiazol-5-yl)-5-
(morpholinocarbamoylamino)indeno[1,2-c]pyrazol-4-one;
 3-(2,4-dimethylthiazol-5-yl)-5-((1-methyl-1-
phenylamino)carbamoylamino)indeno[1,2-c]pyrazol-4-one;
 3-(2,4-dimethylthiazol-5-yl)-5-((2,6-
25 dimethylpiperidino)carbamoylamino)indeno[1,2-c]pyrazol-4-
one; and
 3-(2,4-dimethylthiazol-5-yl)-5-((4-
methylpiperazino)carbamoylamino)indeno[1,2-c]pyrazol-4-one;
 or stereoisomers thereof, N-Oxides thereof,
30 pharmaceutically acceptable salts thereof, and prodrugs thereof.

 [21] Another embodiment of the present invention is a pharmaceutical composition comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of
35 a compound of embodiment [1].

5 [22] In another embodiment, the invention describes a pharmaceutical composition, comprising a pharmaceutically acceptable carrier, a compound according to embodiment [1] or a pharmaceutically acceptable salt or prodrug form thereof, and a cytostatic or cytotoxic agent.

10 [23] In another embodiment, the invention describes a method of treating a cell proliferative disease associated with CDK activity in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to embodiment [1], or a
15 pharmaceutically acceptable salt or prodrug form thereof, wherein the proliferative diseases is selected from the group consisting of: Alzheimer's disease, viral infections, auto-immune diseases, fungal disease, cancer, psoriasis, vascular smooth cell proliferation associated with
20 atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis, neurodegenerative disorders and post-surgical stenosis and restenosis.

 [24] In another embodiment, the invention describes a method of treating cancer associated with CDK activity in a
25 patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof, wherein the cancer is selected from the group consisting of: carcinoma such as
30 bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia,
35 acute lymphoblastic leukemia, B-cell lymphoma, T-cell- lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy

5 cell lymphoma and Burkett's lymphoma; hematopoietic tumors
of myeloid lineage, including acute and chronic myelogenous
leukemias, myelodysplastic syndrome and promyelocytic
leukemia; tumors of mesenchymal origin, including
fibrosarcoma and rhabdomyosarcoma; tumors of the central and
10 peripheral nervous system, including astrocytoma,
neuroblastoma, glioma and schwannomas; other tumors,
including melanoma, seminoma, teratocarcinoma, osteosarcoma,
xeroderma pigmentosum, keratocanthoma, thyroid follicular
cancer and Kaposi's sarcoma.

15 [25] In another embodiment, the invention describes a
method of treating a disease associated with apoptosis in a
patient in need thereof, comprising administering to said
patient a pharmaceutically effective amount of a compound
according to embodiment [1], or a pharmaceutically
20 acceptable salt or prodrug form thereof, wherein the disease
associated with apoptosis is selected from the group
consisting of: cancer, viral infections, autoimmune diseases
and neurodegenerative disorder.

[26] In another embodiment, the invention describes a
25 method of inhibiting tumor angiogenesis and metastasis in a
patient in need thereof, comprising administering to said
patient a pharmaceutically effective amount of a compound
according to embodiment [1], or a pharmaceutically
acceptable salt or prodrug form thereof.

30 [27] In another embodiment, the invention describes a
method of modulating the level of cellular RNA and DNA
synthesis in a patient in need thereof, comprising
administering to said patient a CDK inhibitory effective
amount of a compound according to embodiment [1], or a
35 pharmaceutically acceptable salt or prodrug form thereof.

5 [28] In another embodiment, the invention describes a
method of treating viral infections in a patient in need
thereof, comprising administering to said patient a CDK
inhibitory effective amount of a compound according to
embodiment [1], or a pharmaceutically acceptable salt or
10 prodrug form thereof, wherein the viral infections is
selected from the group consisting of HIV, hepatitis, human
papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus,
Sindbis virus and adenovirus.

 [29] In another embodiment, the invention describes a
15 method of chemopreventing cancer in a patient, comprising
administering to said patient in need thereof, a CDK
inhibitory effective amount of a compound according to
embodiment [1], or a pharmaceutically acceptable salt or
prodrug form thereof.

20 [30] In another embodiment, the invention describes a
method of inhibiting CDK activity comprising combining an
effective amount of a compound according to embodiment [1],
with a composition containing CDK.

 [31] In another embodiment, the invention describes a
25 method of treating cancer associated with CDK activity in a
patient in need thereof, comprising administering to said
patient a pharmaceutically effective amount of a compound
according to embodiment [1], or a pharmaceutically
acceptable salt or prodrug form thereof, in combination
30 (administered together or sequentially) with known anti-
cancer treatments such as radiation therapy or with
cytostatic or cytotoxic agents, wherein such agents are
selected from the group consisting of: DNA interactive
agents, such as cisplatin or doxorubicin; topoisomerase II
35 inhibitors, such as etoposide; topoisomerase I inhibitors
such as CPT-11 or topotecan; tubulin interacting agents,

5 such as paclitaxel, docetaxel or the epothilones; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-fluorouracil; and anti-metabolites, such as methotrexate.

[32] In another embodiment, the invention describes a
10 method treating cell proliferative diseases associated with CDK activity in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof, in
15 combination (administered together or sequentially) with known anti-proliferating agents selected from the group consisting of: altretamine, busulfan, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, thiotepa, cladribine, fluorouracil, floxuridine,
20 gemcitabine, thioguanine, pentostatin, methotrexate, 6-mercaptopurine, cytarabine, carmustine, lomustine, streptozotocin, carboplatin, cisplatin, oxaliplatin, iproplatin, tetraplatin, lobaplatin, JM216, JM335, fludarabine, aminoglutethimide, flutamide, goserelin,
25 leuprolide, megestrol acetate, cyproterone acetate, tamoxifen, anastrozole, bicalutamide, dexamethasone, diethylstilbestrol, prednisone, bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitoxantrone, losoxantrone, mitomycin-c, plicamycin, paclitaxel,
30 docetaxel, CPT-11, epothilones, topotecan, irinotecan, 9-amino camptothecin, 9-nitro camptothecin, GS-211, etoposide, teniposide, vinblastine, vincristine, vinorelbine, procarbazine, asparaginase, pegaspargase, methotrexate, octreotide, estramustine, and hydroxyurea.

35 [33] In another embodiment, the invention describes a method of inhibiting CDK1 activity, comprising administering

5 to a patient in need thereof an effective CDK1 inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

[34] In another embodiment, the invention describes a method of inhibiting CDK2 activity, comprising administering
10 to a patient in need thereof an effective CDK2 inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

[35] In another embodiment, the invention describes a method of inhibiting CDK3 activity, comprising administering
15 to a patient in need thereof an effective CDK3 inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

[36] In another embodiment, the invention describes a method of inhibiting CDK4 activity, comprising administering
20 to a patient in need thereof an effective CDK4 inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

[37] In another embodiment, the invention describes a method of inhibiting CDK5 activity, comprising administering
25 to a patient in need thereof an effective CDK5 inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

[38] In another embodiment, the invention describes a method of inhibiting CDK6 activity, comprising administering
30 to a patient in need thereof an effective CDK6 inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

[39] In another embodiment, the invention describes a method of inhibiting CDK7 activity, comprising administering
35 to a patient in need thereof an effective CDK7 inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

5 [40] In another embodiment, the invention describes a method of inhibiting CDK8 activity, comprising administering to a patient in need thereof, an effective CDK8 inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

10 [41] In another embodiment, the invention describes a method of inhibiting CDK9 activity, comprising administering to a patient in need thereof an effective CDK9 inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

15 [42] In another embodiment, the invention describes a pharmaceutical kit for treating a cell proliferative disease associated with CDK activity, said kit comprising a plurality of separate containers, wherein at least one of said containers contains a compound according to embodiment
20 [1], or a pharmaceutically acceptable salt or prodrug form thereof, and at least another of said containers contains one or more compounds selected from the group consisting of cytostatic or cytotoxic agents, such as for example, but not limited to, DNA interactive agents, such as carboplatin,
25 cisplatin or doxorubicin; topoisomerase II inhibitors, such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan; tubulin interacting agents, such as paclitaxel, taxane, docetaxel or the epothilones; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-
30 fluorouracil; and anti-metabolites, such as methotrexate, and said containers optionally contain a pharmaceutical carrier, which kit may be effectively utilized for carrying out combination therapies according to the invention.

 [43] It is a further embodiment of the invention to
35 provide a method of treating a patient having a disorder associated with excessive cell proliferation, comprising

5 administering to the patient a therapeutically effective amount of a compound of embodiment [1], such that the excessive cell proliferation in the patient is reduced.

[44] In another embodiment, the invention describes a enhanced method of inhibiting CDK activity, comprising
10 adminisitering to a patient in need thereof an efective CDK inhibitory amount of a compound according to embodiment [1], or a pharmaceutically acceptable salt or prodrug form thereof.

It is appreciated that certain feactures of the
15 invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. For example, R^1 and R^2 of embodiment [8] may be combined with R^4 of embodiment [16] to form a single embodiment. Conversely, various feactures of the
20 invention which are, for brevity, described in the context of a single embodiment, may also be provided seperately or in any suitable subcombination.

DETAILED DESCRIPTION OF THE INVENTION

25 As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

Definitions

As used herein, the following terms and expressions
30 have the indicated meanings.

The term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of the invention as herein before described i.e. compounds of formula (I), which expression includes the prodrugs, the pharmaceutically
35 acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates,

5 whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not
10 intended to exclude other instances when the context so permits.

The term "derivative" means a chemically modified compound wherein the modification is considered routine by the ordinary skilled chemist, such as an ester or an amide
15 of an acid, protecting groups, such as a benzyl group for an alcohol or thiol, and tert-butoxycarbonyl group for an amine.

The term "effective amount" means an amount of a compound/composition according to the present invention
20 effective in producing the desired therapeutic effect.

The term "amine protecting group" means an easily removable group which is known in the art to protect an amino group against undesirable reaction during synthetic procedures and to be selectively removable. The use of
25 amine protecting groups is well known in the art for protecting groups against undesirable reactions during a synthetic procedure and many such protecting groups are known, for example, T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons,
30 New York (1991), incorporated herein by reference.

Preferred amine protecting groups are acyl, including formyl, acetyl, chloroacetyl, trichloroacetyl, o-nitrophenylacetyl, o-nitrophenoxycetyl, trifluoroacetyl, acetoacetyl, 4-chlorobutyryl, isobutyryl, o-nitrocinnamoyl,
35 picolinoyl, acylisothiocyanate, aminocaproyl, benzoyl and the like, and acyloxy including methoxycarbonyl, 9-

5 fluorenylmethoxycarbonyl, 2,2,2-trifluoroethoxycarbonyl, 2-trimethylsilylethoxycarbonyl, vinyloxycarbonyl, allyloxycarbonyl, t-butyloxycarbonyl (BOC), 1,1-dimethylpropynyloxycarbonyl, benzyloxycarbonyl (CBZ), p-nitrobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, and
10 the like.

The term "acid labile amine protecting group" means an amine protecting group as defined above which is readily removed by treatment with acid while remaining relatively stable to other reagents. A preferred acid labile amine
15 protecting group is tert-butoxycarbonyl (BOC).

The term "hydrogenation labile amine protecting group" means an amine protecting group as defined above which is readily removed by hydrogenation while remaining relatively stable to other reagents. A preferred hydrogenation labile
20 amine protecting group is benzyloxycarbonyl (CBZ).

The term "hydrogenation labile acid protecting group" means an acid protecting group as defined above which is readily removed by hydrogenation while remaining relatively stable to other reagents. A preferred hydrogenation labile
25 acid protecting group is benzyl.

The term "analogue" means a compound which comprises a chemically modified form of a specific compound or class thereof, and which maintains the pharmaceutical and/or pharmacological activities characteristic of said compound
30 or class.

The term "patient" includes both human and other mammals.

The term "pharmaceutical composition" means a composition comprising a compound of formula (I) and at
35 least one component selected from the group comprising pharmaceutically acceptable carriers, diluents, adjuvants,

5 excipients, or vehicles, such as preserving agents, fillers,
disintegrating agents, wetting agents, emulsifying agents,
suspending agents, sweetening agents, flavoring agents, per-
fuming agents, antibacterial agents, antifungal agents,
lubricating agents and dispensing agents, depending on the
10 nature of the mode of administration and dosage forms.
Examples of suspending agents include ethoxylated isostearyl
alcohols, polyoxyethylene sorbitol and sorbitan esters,
microcrystalline cellulose, aluminum metahydroxide,
bentonite, agar-agar and tragacanth, or mixtures of these
15 substances. Prevention of the action of microorganisms can
be ensured by various antibacterial and antifungal agents,
for example, parabens, chlorobutanol, phenol, sorbic acid,
and the like. It may also be desirable to include isotonic
agents, for example sugars, sodium chloride and the like.
20 Prolonged absorption of the injectable pharmaceutical form
can be brought about by the use of agents delaying
absorption, for example, aluminum monostearate and gelatin.
Examples of suitable carriers, diluents, solvents or
vehicles include water, ethanol, polyols, suitable mixtures
25 thereof, vegetable oils (such as olive oil) and injectable
organic esters such as ethyl oleate. Examples of excipients
include lactose, milk sugar, sodium citrate, calcium
carbonate, dicalcium phosphate phosphate. Examples of
disintegrating agents include starch, alginic acids and
30 certain complex silicates. Examples of lubricants include
magnesium stearate, sodium lauryl sulphate, talc, as well as
high molecular weight polyethylene glycols.

The term "solvate" means a physical association of a
compound of this invention with one or more solvent
35 molecules. This physical association includes hydrogen
bonding. In certain instances the solvate will be capable

5 of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates. Exemplary solvates include hydrates, ethanolates, methanolates, and the like.

10 The term "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and
15 s-pentyl. In addition, the term is intended to include both unsubstituted and substituted alkyl groups, the latter referring to alkyl moieties having one or more hydrogen substituents replaced by, but not limited to halogen, hydroxyl, carbonyl, alkoxy, ester, ether, cyano, phosphoryl,
20 amino, imino, amido, sulfhydryl, alkythio, thioester, sulfonyl, nitro, heterocyclo, aryl or heteroaryl. It will also be understood by those skilled in the art that the substituted moieties themselves can be substituted as well when appropriate.

25 The terms "halo" or "halogen" as used herein refer to fluoro, chloro, bromo and iodo. The term "aryl" is intended to mean an aromatic moiety containing the specified number of carbon atoms, such as, but not limited to phenyl, indanyl or naphthyl. The terms "cycloalkyl" and "bicycloalkyl" are
30 intended to mean any stable ring system, which may be saturated or partially unsaturated. Examples of such include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, bicyclo[2.2.2]nonane, adamantyl, or tetrahydronaphthyl (tetralin).

35 As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic

5 or bicyclic or 7- to 13-membered bicyclic or tricyclic, any
of which may be saturated, partially unsaturated, or
aromatic. Examples of such carbocycles include, but are not
limited to, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, adamantyl, cyclooctyl;
10 [3.3.0]bicyclooctane, [4.3.0]bicyclononane,
[4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane,
fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or
tetrahydronaphthyl (tetralin).

As used herein, the term "heterocycle" or "heterocyclic
15 system" is intended to mean a heterocyclyl, heterocycleny,
or heteroaryl groups as described herein, which consists of
carbon atoms and from 1 to 4 heteroatoms independently
selected from the group consisting of N, O and S and
including any bicyclic group in which any of the above-
20 defined heterocyclic rings is fused to a benzene ring. The
nitrogen and sulfur heteroatoms may optionally be oxidized.
The heterocyclic ring may be attached to its pendant group
at any heteroatom or carbon atom which results in a stable
structure. The heterocyclic rings described herein may be
25 substituted on carbon or on a nitrogen atom if the resulting
compound is stable. If specifically noted, a nitrogen in
the heterocycle may optionally be quaternized. It is
preferred that when the total number of S and O atoms in the
heterocycle exceeds 1, then these heteroatoms are not
30 adjacent to one another. It is preferred that the total
number of S and O atoms in the heterocycle is not more than
1.

Examples of heterocycles include, but are not limited
to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl,
35 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-
quinolizinyll, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl,

- 5 benzimidazolyl, benzofuranyl, benzothiofuranyl,
benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl,
benztetrazolyl, benzisoxazolyl, benzisothiazolyl,
benzimidazalonyl, carbazolyl, 4aH-carbazolyl, b-carbolinyl,
chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl,
10 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran,
furanyl, furazanyl, imidazolidinyl, imidazolinyl,
imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indoliziny,
indolyl, isobenzofuranyl, isochromanyl, isoindazolyl,
isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl,
15 isoxazolyl, morpholinyl, naphthyridinyl,
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,
oxazolidinyl., oxazolyl, oxazolidinylperimidinyl,
phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl,
20 phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl,
piperazinyl, piperidinyl, pteridinyl, piperidonyl,
4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl,
pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl,
25 pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl,
quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxalinyl,
quinuclidinyl, carbolinyl, tetrahydrofuranyl,
tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-
thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-
30 thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl,
thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl,
thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl,
1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl. Preferred
heterocycles include, but are not limited to, pyridinyl,
35 furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl,
benzimidazolyl, 1H-indazolyl, oxazolidinyl, benzotriazolyl,

5 benzisoxazolyl, oxindolyl, benzoxazoliny, or isatinoyl.
Also included are fused ring and spiro compounds containing,
for example, the above heterocycles.

"Heterocyclenyl" means a non-aromatic monocyclic or
multicyclic hydrocarbon ring system of about 3 to about 10
10 atoms, preferably about 4 to about 8 atoms, in which one or
more of the carbon atoms in the ring system is/are hetero
element(s) other than carbon, for example nitrogen, oxygen
or sulfur atoms, and which contains at least one carbon-
carbon double bond or carbon-nitrogen double bond.
15 Preferred ring sizes of rings of the ring system include
about 5 to about 6 ring atoms. The designation of the aza,
oxa or thia as a prefix before heterocyclenyl define that at
least a nitrogen, oxygen or sulfur atom is present
respectively as a ring atom. The heterocyclenyl may be
20 optionally substituted by one or R^4 substituents as defined
herein. The nitrogen or sulphur atom of the heterocyclenyl
may also be optionally oxidized to the corresponding
N-oxide, S-oxide or S,S-dioxide. "Heterocyclenyl" as used
herein includes by way of example and not limitation those
25 described in Paquette, Leo A. ; "Principles of Modern
Heterocyclic Chemistry" (W. A. Benjamin, New York, 1968),
particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry
of Heterocyclic Compounds, A series of Monographs" (John
Wiley & Sons, New York, 1950 to present), in particular
30 Volumes 13, 14, 16, 19, and 28; and "J. Am. Chem. Soc. ",
82:5566 (1960). Exemplary monocyclic azaheterocyclenyl
groups include 1,2,3,4- tetrahydrohydropyridine,
1,2-dihydropyridyl, 1,4-dihydropyridyl,
1,2,3,6-tetrahydropyridine, 1,4,5,6-tetrahydropyrimidine, 2-
35 pyrrolinyl, 3-pyrrolinyl, 2-imidazoliny, 2-pyrazoliny, and
the like. Exemplary oxaheterocyclenyl groups include 3,4-

5 dihydro-2H-pyran, dihydrofuranyl, and fluorodihydrofuranyl.
Preferred is dihydrofuranyl. An exemplary multicyclic
oxaheterocyclenyl group is 7-oxabicyclo[2.2.1]heptenyl.
Preferred monocyclic thiaheterocyclenyl rings include
dihydrothiophenyl and dihydrothiopyranyl; more preferred is
10 dihydrothiophenyl.

"Heterocyclyl" means a non-aromatic saturated
monocyclic or multicyclic ring system of about 3 to about 10
carbon atoms, preferably about 4 to about 8 carbon atoms, in
which one or more of the carbon atoms in the ring system
15 is/are hetero element(s) other than carbon, for example
nitrogen, oxygen or sulfur. Preferred ring sizes of rings
of the ring system include about 5 to about 6 ring atoms.
The designation of the aza, oxa or thia as a prefix before
heterocyclyl define that at least a nitrogen, oxygen or
20 sulfur atom is present respectively as a ring atom. The
heterocyclyl may be optionally substituted by one or more R⁴
substituents which may be the same or different, and are as
defined herein. The nitrogen or sulphur atom of the
heterocyclyl may also be optionally oxidized to the
25 corresponding N-oxide, S-oxide or S,S-dioxide.

"Heterocyclyl" as used herein includes by way of example and
not limitation those described in Paquette, Leo A. ;
"Principles of Modern Heterocyclic Chemistry" (W. A.
Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6,
30 7, and 9; "The Chemistry of Heterocyclic Compounds, A series
of Monographs" (John Wiley & Sons, New York, 1950 to
present), in particular Volumes 13, 14, 16, 19, and 28; and
"J. Am. Chem. Soc. ", 82:5566 (1960). Exemplary monocyclic
heterocyclyl rings include piperidyl, pyrrolidinyl,
35 piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl,

5 1,3-dioxolanyl, 1,4-dioxanyl, tetrahydrofuranyl,
tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

"Heteroaryl" means an aromatic monocyclic or
multicyclic ring system of about 5 to about 10 atoms, in
which one or more of the atoms in the ring system is/are
10 hetero element(s) other than carbon, for example nitrogen,
oxygen or sulfur. Preferred ring sizes of rings of the ring
system include about 5 to about 6 ring atoms. The
"heteroaryl" may also be substituted by one or more R₄
substituents which may be the same or different, and are as
15 defined herein. The designation of the aza, oxa or thia as
a prefix before heteroaryl define that at least a nitrogen,
oxygen or sulfur atom is present respectively as a ring
atom. A nitrogen atom of an heteroaryl may be optionally
oxidized to the corresponding N-oxide. Heteroaryl as used
20 herein includes by way of example and not limitation those
described in Paquette, Leo A. ; "Principles of Modern
Heterocyclic Chemistry" (W. A. Benjamin, New York, 1968),
particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry
of Heterocyclic Compounds, A series of Monographs" (John
25 Wiley & Sons, New York, 1950 to present), in particular
Volumes 13, 14, 16, 19, and 28; and "J. Am. Chem. Soc. ",
82:5566 (1960). Exemplary heteroaryl and substituted
heteroaryl groups include pyrazinyl, thienyl, isothiazolyl,
oxazolyl, pyrazolyl, furazanyl, pyrrolyl, 1,2,4-
30 thiadiazolyl, pyridazinyl, quinoxalinyl, phthalazinyl,
imidazo[1,2-a]pyridine, imidazo[2,1-b]thiazolyl,
benzofurazanyl, azaindolyl, benzimidazolyl, benzothienyl,
thienopyridyl, thienopyrimidyl, pyrrolopyridyl,
imidazopyridyl, benzoazaindole, 1,2,4-triazinyl,
35 benzthiazolyl, furanyl, imidazolyl, indolyl, indolizinyll,
isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl,

5 pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinoliny, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl. Preferred heteroaryl groups include pyrazinyl, thienyl, pyridyl, pyrimidinyl, isoxazolyl and isothiazolyl.

10 As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid
15 salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-
20 toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic,
25 succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

30 The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a
35 stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two;

5 generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, PA, 1990, p. 1445, the disclosure of which is hereby
10 incorporated by reference.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the
15 tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio.

The term "Pharmaceutically acceptable prodrugs" as used
20 herein means those prodrugs of the compounds useful according to the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like,
25 commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.

The term "Prodrugs", as the term is used herein, are
30 intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (i.e., solubility,
35 bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Thus,

5 the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same, and compositions containing the same. Prodrugs of the present invention are prepared by modifying functional groups present in the compound in such a way that the
10 modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. The transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or
15 oxidation of a susceptible functionality. Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free
20 amino, or free sulfhydryl group, respectively. Functional groups which may be rapidly transformed, by metabolic cleavage, in vivo form a class of groups reactive with the carboxyl group of the compounds of this invention. They include, but are not limited to such groups as alkanoyl
25 (such as acetyl, propionyl, butyryl, and the like), unsubstituted and substituted aroyl (such as benzoyl and substituted benzoyl), alkoxycarbonyl (such as ethoxycarbonyl), trialkylsilyl (such as trimethyl- and triethysilyl), monoesters formed with dicarboxylic acids
30 (such as succinyl), and the like. Because of the ease with which the metabolically cleavable groups of the compounds useful according to this invention are cleaved in vivo, the compounds bearing such groups act as pro-drugs. The compounds bearing the metabolically cleavable groups have
35 the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption

5 conferred upon the parent compound by virtue of the presence
of the metabolically cleavable group. A thorough discussion
of prodrugs is provided in the following: Design of
Prodrugs, H. Bundgaard, ed., Elsevier, 1985; Methods in
Enzymology, K. Widder et al, Ed., Academic Press, 42, p.309-
10 396, 1985; A Textbook of Drug Design and Development,
Krogsgaard-Larsen and H. Bundgaard, ed., Chapter 5; "Design
and Applications of Prodrugs" p.113-191, 1991; Advanced Drug
Delivery Reviews, H. Bundgaard, 8, p.1-38, 1992; Journal of
Pharmaceutical Sciences, 77, p. 285, 1988; Chem. Pharm.
15 Bull., N. Nakeya et al, 32, p. 692, 1984; Pro-drugs as
Novel Delivery Systems, T. Higuchi and V. Stella, Vol. 14 of
the A.C.S. Symposium Series, and Bioreversible Carriers in
Drug Design, Edward B. Roche, ed., American Pharmaceutical
Association and Pergamon Press, 1987, which are incorporated
20 herein by reference.

"Substituted" is intended to indicate that one or more
hydrogens on the atom indicated in the expression using
"substituted" is replaced with a selection from the
indicated group(s), provided that the indicated atom's
25 normal valency is not exceeded, and that the substitution
results in a stable compound. When a substituent is keto
(i.e., =O) group, then 2 hydrogens on the atom are replaced.

The term "Treating" refers to:

- 30 (i) preventing a disease, disorder or condition from
occurring in an animal which may be predisposed to the
disease, disorder and/or condition but has not yet
been diagnosed as having it;
(ii) inhibiting the disease, disorder or condition, i.e.,
arresting its development; and

- 5 (iii) relieving the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.

Preparation of Compounds of the Invention

10 It will be apparent to those skilled in the art that certain compounds of formula (I) can exhibit isomerism, for example geometrical isomerism, e.g., E or Z isomerism, and optical isomerism, e.g., R or S configurations. Geometrical isomers include the cis and trans forms of compounds of the
15 invention having alkenyl moieties. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a
20 structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallization techniques,
25 or they are separately prepared from the appropriate isomers of their intermediates, for example by the application or adaptation of methods described herein.

The compounds of the present invention are useful in the form of the free base or acid or in the form of a
30 pharmaceutically acceptable salt thereof. All forms are within the scope of the invention.

Where the compound of the present invention is substituted with a basic moiety, acid addition salts are formed and are simply a more convenient form for use; and in
35 practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare

5 the acid addition salts include preferably those which
produce, when combined with the free base, pharmaceutically
acceptable salts, that is, salts whose anions are non-toxic
to the patient in pharmaceutical doses of the salts, so that
the beneficial inhibitory effects on CDK inherent in the
10 free base are not vitiated by side effects ascribable to the
anions. Although pharmaceutically acceptable salts of said
basic compounds are preferred, all acid addition salts are
useful as sources of the free base form even if the
particular salt, per se, is desired only as an intermediate
15 product as, for example, when the salt is formed only for
purposes of purification, and identification, or when it is
used as intermediate in preparing a pharmaceutically
acceptable salt by ion exchange procedures.

According to a further feature of the invention, acid
20 addition salts of the compounds of this invention are
prepared by reaction of the free base with the appropriate
acid, by the application or adaptation of known methods.
For example, the acid addition salts of the compounds of
this invention are prepared either by dissolving the free
25 base in aqueous or aqueous-alcohol solution or other
suitable solvents containing the appropriate acid and
isolating the salt by evaporating the solution, or by
reacting the free base and acid in an organic solvent, in
which case the salt separates directly or can be obtained by
30 concentration of the solution.

The acid addition salts of the compounds of this
invention can be regenerated from the salts by the
application or adaptation of known methods. For example,
parent compounds of the invention can be regenerated from
35 their acid addition salts by treatment with an alkali, e.g.

5 aqueous sodium bicarbonate solution or aqueous ammonia solution.

Where the compound of the invention is substituted with an acidic moiety, base addition salts may be formed and are simply a more convenient form for use; and in practice, use
10 of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the
15 animal organism in pharmaceutical doses of the salts, so that the beneficial inhibitory effects on CDK inherent in the free acid are not vitiated by side effects ascribable to the cations. Pharmaceutically acceptable salts, including for example alkali and alkaline earth metal salts, within
20 the scope of the invention are those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine,
25 ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like.

30 Metal salts of compounds of the present invention may be obtained by contacting a hydride, hydroxide, carbonate or similar reactive compound of the chosen metal in an aqueous or organic solvent with the free acid form of the compound. The aqueous solvent employed may be water or it may be a
35 mixture of water with an organic solvent, preferably an alcohol such as methanol or ethanol, a ketone such as

5 acetone, an aliphatic ether such as tetrahydrofuran, or an ester such as ethyl acetate. Such reactions are normally conducted at ambient temperature but they may, if desired, be conducted with heating.

Amine salts of compounds of the present invention may
10 be obtained by contacting an amine in an aqueous or organic solvent with the free acid form of the compound. Suitable aqueous solvents include water and mixtures of water with alcohols such as methanol or ethanol, ethers such as tetrahydrofuran, nitriles such as acetonitrile, or ketones
15 such as acetone. Amino acid salts may be similarly prepared.

The base addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For example,
20 parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.

Pharmaceutically acceptable salts also include quaternary lower alkyl ammonium salts. The quaternary salts
25 are prepared by the exhaustive alkylation of basic nitrogen atoms in compounds, including nonaromatic and aromatic basic nitrogen atoms, according to the invention, i.e., alkylating the non-bonded pair of electrons of the nitrogen moieties with an alkylating agent such as methylhalide, particularly
30 methyl iodide, or dimethyl sulfate. Quaternarization results in the nitrogen moiety becoming positively charged and having a negative counter ion associated therewith.

As will be self-evident to those skilled in the art, some of the compounds of this invention do not form stable
35 salts. However, acid addition salts are more likely to be formed by compounds of this invention having a nitrogen-

5 containing heteroaryl group and/or wherein the compounds contain an amino group as a substituent. Preferable acid addition salts of the compounds of the invention are those wherein there is not an acid labile group.

As well as being useful in themselves as active
10 compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those
15 skilled in the art.

Compounds according to the invention, for example, starting materials, intermediates or products, are prepared as described herein or by the application or adaptation of known methods, by which is meant methods used heretofore or
20 described in the literature.

Compounds useful according to the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R. C. Larock
25 in Comprehensive Organic Transformations, VCH publishers, 1989.


In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these
30 are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Green and P.G.M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991; J. F. W.
35 McOmie in "Protective Groups in Organic Chemistry" Plenum Press, 1973.

5 Preferred methods of synthesizing the compounds of the invention include, but are not limited to, those methods described below. Additional methods for synthesizing the compounds of this invention can be found in WO 99/54308 which is incorporated herein in its entirety. Each of the
10 references cited below are hereby incorporated herein by reference.

The compounds of formula I can be prepared by the chemistry described in Scheme 1. 2,4-Dimethyl-5-acetylthiazole was converted to the 1,3-diketone 2 by
15 treatment with sodium ethoxide and ethyl trifluoroacetate. Condensation of diketone 2 with 3-nitrophthalic anhydride (3) using the conditions described in Rotberg and Oshkaya, Zh. Organ. Khim. 8:84-87, 1972; Zh. Organ. Khim. 9:2548-2550, 1973, the contents of which are hereby incorporated
20 herein by reference, gave nitrotriketone 4. Additional means of preparing triketones are known to one skilled in the art as described in Kilgore et al, Industrial and Engineering Chemistry 34:494-497, 1946, the contents of which are hereby incorporated herein by reference.
25 Reduction of the nitro to the aniline (5) was effected using zinc and calcium chloride. The aniline (5) was reacted with phenyl chloroformate and the resulting carbamate 6 was converted to the semicarbazide using the appropriate hydrazine. The triketone was converted to the indeno[1,2-
30 c]pyrazol-4-one ring system (I) with hydrazine in refluxing ethanol. Additional means of preparing indeno[1,2-c]pyrazol-4-ones are known to one skilled in the art as described in Lemke et al., J. Heterocyclic Chem. 19:1335-1340, 1982; Mosher and Soeder, J. Heterocyclic Chem. 8:855-
35 59, 1971; Hrncliar and Svanygova Collect. Czech. Chem.

5 Commun. 59:2734-40, 1994 the contents of which are hereby incorporated herein by reference.

Scheme 1




10

An alternative method for making compounds of the present invention is shown in Scheme 2. The intermediate aniline 5 can be acetylated and cyclized to the pyrazole 9 using the same conditions previously described in Scheme 1.

15 Removal of the acetyl group with strong acid followed by protection of the pyrazole nitrogen gave aniline 11. Conversion of the aniline (11) to the phenyl carbamate 12 followed by treatment with the appropriate hydrazine gave


- 5 the protected semicarbazide 13. Removal of the 2-(trimethylsilyl)ethoxymethyl (SEM) protecting group using hydrochloric acid provided the pyrazole (I).

Scheme 2



5 Another method for making compounds of the present invention is presented in Scheme 3. Aniline 5 can be directly converted to the semicarbazide 7 using the preformed carbamate 14. Reagents such as 14 are readily prepared in advance by one skilled in the art using the
10 appropriate hydrazine and phenyl chloroformate. Cyclization of the triketone 7 proceeded as previously described in Scheme 1.

Scheme 3



15


EXAMPLES

Abbreviations used in the Examples are defined as follows: "°C" for degrees Celsius, "ESI-MS" for electrospray
20 ionization mass spectroscopy, "g" for gram or grams, "h" for hour or hours, "mg" for milligram or milligrams, "mL" for milliliter or milliliters, "mmol" for millimolar, "M" for molar, "min" for minute or minutes, "HPLC" for high pressure liquid chromatography.

5

Example 1

Preparation of 3-(2,4-dimethylthiazol-5-yl)-5-(carbamoylamino)indeno[1,2-c]pyrazol-4-one



10

Step 1. Synthesis of nitrotriketone 4 from 1.

Ethyl trifluoroacetate (22.9 g, 161 mmol) and 2,4-dimethyl-5-acetylthiazole (25.0 g, 161 mmol) were added to a solution of sodium ethoxide, freshly prepared from sodium (3.71 g, 161 mmol) and ethanol (500 mL), and stirred at 23 °C for 12 h. Half of the volume of organic solvent was

5 concentrated in vacuo and the reaction mixture was diluted
with 6 M HCl (400 mL) and extracted with ethyl acetate (2 X
300 mL). The combined organic extracts were washed with
brine (2 X 300 mL), dried (MgSO_4), filtered, and
concentrated in vacuo to give 1,3-diketone 2 as an orange
10 oil which was used without purification.

3-Nitrophthalic anhydride (31.1 g, 161 mmol) was added
to a solution of diketone 2 in acetic anhydride (91.2 mL,
968 mmol). The reaction mixture was cooled to 0 °C and
triethylamine (67.3 mL, 484 mmol) was added dropwise over 1
15 h. The reaction mixture was warmed to 23 °C and stirred for
12 h, heated to 50 °C for 30 min, and then cooled to 23 °C.
The reaction mixture was slowly poured into 1 M HCl (484 mL,
diluted with 1 L of water). The solid which precipitated
was filtered and washed repeatedly with water (3 X 150 mL)
20 to give a brown solid (24.4 g, 46%, 2 steps). ESI-MS (M-H)
found for $\text{C}_{15}\text{H}_9\text{N}_2\text{O}_5\text{S}$: 329.

Step 2. Synthesis of aniline 5 from 4.

25 A solution of nitrotriketone 4 (24.4 g, 73.9 mmol),
zinc powder (160 g, 2.4 mol), and calcium chloride (5.3 g,
48 mmol) in 4:1 ethanol/water (370 mL) was heated to reflux
for 1 h. The reaction mixture was filtered over celite and
washed with methanol (3 X 150 mL) and ethyl acetate (3 X 150
30 mL). The filtrate was concentrated in vacuo to give a crude
brown solid. Purification by flash column chromatography
(silica, chloroform \rightarrow 2% methanol/chloroform \rightarrow 5%
methanol/chloroform \rightarrow 7% methanol/chloroform) gave aniline 5
(13.0 g, 59%) as a brown solid. ESI-MS (M-H) found for
35 $\text{C}_{15}\text{H}_{11}\text{N}_2\text{O}_3\text{S}$: 299.

5 Step 3. Synthesis of carbamate 6 from 5.

A solution of aniline 5 (840 mg, 2.8 mmol), phenyl
chloroformate (0.42 mL, 3.4 mmol), and sodium carbonate (1.6
g) in acetone (14 mL) was heated to 50 °C for 4 h. The
10 reaction mixture was cooled to 23 °C and diluted with water
(20 mL) and ethyl acetate (20 mL). The organic layer was
separated and washed with brine (20 mL), dried (MgSO₄),
filtered, and concentrated in vacuo to give a crude brown
solid. Trituration with ether gave carbamate 6 (1.18 g,
15 99%) as a brown solid. ESI-MS (M-H) found for C₂₂H₁₅N₂O₅S:
419.

Step 4. Synthesis of urea 15 from 6.

20 A solution of carbamate 6 (1.18 g, 2.8 mmol) and
ammonium hydroxide (0.47 mL, 3.4 mmol) in N,N-
dimethylformamide (5 mL) was heated to 90 °C for 1 h. The
solvent was concentrated in vacuo to give a crude residue.
Purification using reverse phase HPLC
25 (acetonitrile/water/trifluoroacetic acid) gave the product
as a yellow solid (117 mg, 12%). ESI-MS (M-H) found for
C₁₆H₁₂N₃O₄S: 342.

Step 5. Synthesis of pyrazole 16 from 15.


30

A solution of urea 15 (117 mg, 0.34 mmol), hydrazine
(21 µL, 0.68 mmol), and p-toluenesulfonic acid (3.2 mg, 17
µmol) in ethanol (1.7 mL) was refluxed for 4 h. The
reaction mixture was cooled to 23 °C and concentrated in
35 vacuo to give a crude residue. Purification using reverse
phase HPLC (acetonitrile/water/trifluoroacetic acid) gave

5 the product as its TFA-salt (10 mg, 9%). ESI-MS (M+H)
calc'd for C₁₆H₁₄N₅O₂S: 340.0868, found: 340.0895.

Example 2


Preparation of 3-(2,4-dimethylthiazol-5-yl)-5-
10 (morpholinocarbamoylamino)indeno[1,2-c]pyrazol-4-one



Prepared in a similar fashion as described for example
15 1 using 6 and morpholine as the starting materials. mp >300
°C (TFA salt); ESI-MS (M+H) calc'd for C₂₀H₂₁N₆O₃S:
425.1396, found: 425.1424.

Example 3

20 Preparation of 3-(2,4-dimethylthiazol-5-yl)-5-((1-methyl-1-
phenylamino)carbamoylamino)indeno[1,2-c]pyrazol-4-one



Step 1. Synthesis of acetamide 8 from 5.

A solution of aniline 5 (3.3 g, 10.8 mmol) in N,N-dimethylformamide (54 mL) was treated with acetyl chloride (0.81 mL, 11.4 mmol) and triethylamine (1.7 mL, 11.9 mmol)

5 and refluxed for 4h. The reaction mixture was cooled to 23 °C and diluted with ethyl acetate (100 mL) and water (100 mL). The aqueous layer was separated and washed with ethyl acetate (100 mL). The combined organic extracts were washed with brine (100 mL), dried (MgSO₄), filtered, and
10 concentrated in vacuo to give a crude brown solid. The solid was dissolved in a small amount of methylene chloride (~10 mL) and treated with ether. The solid which precipitated was filtered and washed with ether (3 X 100 mL) to give a brown solid (1.6 g, 43%). ESI-MS (M-H) found for
15 C₁₇H₁₃N₂O₄S: 341.

Step 2. Synthesis of pyrazole 9 from 8.

A solution of triketone 8 (1.6 g, 4.7 mmol), hydrazine
20 (0.71 mL, 9.4 mmol), and p-toluenesulfonic acid (44 mg, 0.23 mmol) in ethanol (23 mL) was refluxed for 4 h. The reaction mixture was cooled to 23 °C and the solid was filtered and washed with ethanol (20 mL) and ether (20 mL). Recrystallization of the precipitate from ethanol gave the
25 product as a brown solid (400 mg, 25%). ESI-MS (M-H) found for C₁₇H₁₃N₄O₂S: 337.

Step 3. Synthesis of aniline 10 from 9.

30 A solution of pyrazole 9 (400 mg, 1.2 mmol) and concentrated hydrochloric acid (2 mL) in methanol was refluxed for 3 h. The reaction mixture was cooled to 23 °C and concentrated in vacuo to give the product as a yellow solid (350 mg, 99%). ESI-MS (M-H) found for C₁₅H₁₁N₄O₂S:
35 295.

5 Step 4. Synthesis of aniline 11 from 10.

A solution of aniline 10 (350 mg, 1.2 mmol) in dioxane (6 mL) was treated with triethylamine (0.69 mL, 5 mmol) and 2-(trimethylsilyl)ethoxymethyl chloride (0.52 mL, 3 mmol) and heated to reflux for 3 h. The reaction mixture was cooled to 23 °C and diluted with EtOAc (20 mL) and water (20 mL). The aqueous layer was separated and extracted with ethyl acetate (20 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO₄), filtered, and concentrated in vacuo to give a yellow solid. The yellow solid was treated with methylene chloride (50 mL) and methanol (50 mL) and filtered. The filtrate was concentrated in vacuo to give a crude brown residue. Purification by flash column chromatography (silica, 10% ethyl acetate/hexane → 20% ethyl acetate/hexane → 40% ethyl acetate/hexane → 80% ethyl acetate/hexane) gave aniline 11 (235 mg, 47%) as a brown solid. ESI-MS (M+H) found for C₂₁H₂₇N₄O₂SSi: 427.

25 Step 5. Synthesis of carbamate 12 from 11.

Prepared in a similar fashion as described for example 1, step 3, using aniline 11 as the starting material. ESI-MS (M+H) found for C₂₈H₃₁N₄O₄SSi: 547.

30

Step 6. Synthesis of pyrazole 17 from 12.

A solution of carbamate 12 (167 mg, 0.3 mmol) and 1-methyl-1-phenylhydrazine (72 µL, 0.6 mmol) in dimethyl sulfoxide (2 mL) was heated to 90 °C for 1 h. The solvent was concentrated in vacuo to give a crude residue which was


5 diluted with 1:1 acetonitrile/water (3 mL). The solid which precipitated was filtered to give the product as a yellow solid (110 mg, 63%). ESI-MS (M+H) found for C₂₉H₃₅N₆O₃SSi: 574.

10 Step 7. Synthesis of pyrazole 18 from 17.

A solution of 17 (110 mg, 0.2 mmol) in ethanol (10 mL) was treated with 4M hydrochloric acid in dioxane (10 mL) and heated to 70 °C for 1 h. The reaction mixture was cooled to 15 23 °C and the solid which precipitated was filtered to give the product as its HCl-salt (50 mg, 59%). mp = 250 °C; ESI-MS (M+H) calc'd for C₂₃H₂₁N₆O₂S: 445.1447, found: 445.1432.

Example 4

20 Preparation of 3-(2,4-dimethylthiazol-5-yl)-5-((2,6-dimethylpiperidino)carbamoylamino)indeno[1,2-c]pyrazol-4-one




25 Prepared in a similar fashion as described for example 3 using 12 and 1-amino-2,6-dimethylpiperidine as the starting materials. ESI-MS (M+H) found for C₂₃H₃₇N₆O₂S: 451.

5

Example 5

Preparation of 3-(2,4-dimethylthiazol-5-yl)-5-((4-methylpiperazino) carbamoylamino)indeno[1,2-c]pyrazol-4-one



10

Step 1. Synthesis of semicarbazide 19 from aniline 5.

A solution of aniline 5 (13.0 g, 43.3 mmol), N-(4-methylpiperazinyl)-O-(phenyl)carbamate (20.4 g, 86.7 mmol), and triethylamine (18.1 mL, 130 mmol) in dimethylsulfoxide (217 mL) was heated to 90 °C for 1 h. The reaction mixture was cooled to 23 °C and diluted with water (500 mL). The solid which precipitated was collected and washed with water (300 mL), ethanol (300 mL), and ether (300 mL) and dried to give a brown solid (15.6 g, 82%). ESI-MS (M+H) calc'd for C₂₁H₂₄N₅O₄S: 442.1549, found: 442.1531.

5 Step 2. Synthesis of pyrazole 20 from semicarbazide 19.

A solution of semicarbazide 19 (15.6 g, 35.3 mmol), hydrazine (6.7 mL, 212 mmol), and acetic acid (4.0 mL, 71 mmol) was refluxed in ethanol (354 mL) for 84 h. The
10 reaction mixture was cooled to 23 °C, filtered, washed with ethanol (300 mL) and ether (300 mL), and dried to give a yellow solid which was dissolved in 10% acetic acid in water (20 mL). The solution was adjusted to pH = 7 with 10% sodium hydroxide. The solid which precipitated was filtered
15 and dried to give the free base (6.8 g, 29%) as a yellow solid. The free base was dissolved in 1M hydrochloric acid (31 mL) and the water was removed with a lyophilizer to give the product as a light brown powder (7.9 g, 99% from the free base). mp = 278 °C; ESI-MS (M+H) calc'd for
20 C₂₁H₂₄N₇O₂S: 438.1712, found: 438.1714.

UTILITY

Inhibition of Kinase/Cyclin Complex Enzymatic Activity

The compounds of this invention were assayed for their inhibitory activity against CDK2/E kinase complexes (see WO
25 99/54308 for descriptions of these assays).

Inhibition of HCT 116 Cancer Cell Proliferation

The cellular activity of the compounds disclosed in this invention were examined using cultured HCT116 cells
30 (see WO 99/54308 for descriptions of this assay).

Inhibition of AG1523 Fibroblast Cells

To test the ability of several compounds disclosed in this invention to kill arrested, normal human cells, we
35 examined the effect of these compounds on cultured AG1523 cells, a human foreskin fibroblast primary cell line. This


5 assay was designed such that a decrease in absorbance, as
measured by a cytotoxicity test using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
as an indicator of metabolic activity (Carmichael, James et
al., "Evaluation of a Tetrazolium-based Semiautomated
10 Colorimetric Assay: Assessment of Chemosensitivity Testing."
Cancer Research 47, 936-942, February 15, 1987), is observed
in treated cells only in the event that the treated cells
undergo death. Briefly, AG1523 cells are cultured as
confluent monolayers which are G1-arrested due to contact
15 inhibition in the presence of test compounds at increasing
concentrations. At selected time points, MTT is added to
groups of cells. Mitochondrial dehydrogenase of viable
cells reduced the MTT to a blue formazan product which was
solubilized in 0.04N HCl in isopropyl alcohol and measured
20 spectrophotometrically.

5

CLAIMS

What is claimed is:

1. A novel compound of formula (I):



10

or stereoisomers thereof, N-Oxides thereof, pharmaceutically acceptable salts thereof, and prodrugs thereof, wherein:

R is independently at each occurrence selected from the group: H, NR^1R^2 , $\text{NR}^1\text{C}(\text{O})\text{R}^3$, $\text{NR}^1\text{C}(\text{O})\text{OR}^5$, $\text{NHC}(\text{O})\text{NR}^1\text{R}^2$,

15 $\text{NHC}(\text{S})\text{NR}^1\text{R}^2$, and 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with 0-4 R^4 substituents;

R^1 is selected from the group: H, halo, -CN, C_{1-4} haloalkyl, C_{1-4} alkyl, phenyl, and benzyl;

20 R^2 is selected from the group: H, C_{1-4} alkyl, phenyl, and benzyl;

alternatively, R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocycl group or a 4-8 membered heterocyclenyl group containing an
25 additional 0-1 N, S, or O atom, wherein the heterocycl or heterocyclenyl group is substituted with 0-4 R^4 substituents;

R^3 is selected from the group: H, halo, -CN, C_{1-4} haloalkyl, C_{1-4} alkyl, phenyl, and benzyl; and

- 5 R^4 is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.
- R^5 is selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl.
- 10 2. A compound according to claim 1, wherein:
R is a 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with 0-3 R^4 substituents.
- 15 3. A compound according to claim 1, wherein:
R is a 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with 0-2 R^4 substituents.
- 20 4. A compound according to claim 1, wherein:
R is a 5-10 membered heterocycle containing from 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with a R^4 substituent.
- 25 5. A compound according to claim 1, wherein:
R is a 5-6 membered heteroaryl, heterocyclyl, or heterocyclenyl group, substituted with 0-3 R^4 substituents.
6. A compound according to claim 1, wherein:
- 30 R is H or NR^1R^2 ;
 R^1 is selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl;
 R^2 is selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl;

5 alternatively, R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocycl group or a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocycl or heterocyclenyl group is substituted with 0-3 R^4

10 substituents; and

R^4 is selected from the group: , halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

7. A compound according to claim 1, wherein:

15 R is H or NR^1R^2 ;

R^1 is selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl; and

R^2 is selected from the group: H, C₁₋₄ alkyl, phenyl, and benzyl.

20

8. A compound according to claim 1, wherein:

R is H or NR^1R^2 ;

R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocycl group containing an
25 additional 0-1 N, S, or O atom, wherein the heterocycl is substituted with 0-3 R^4 substituents; and

R^4 is selected from the group: , halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

30 9. A compound according to claim 1, wherein:

R is H or NR^1R^2 ;

R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclclyl group containing

5 an additional 0-1 N, S, or O atom, wherein the heterocyclyl is substituted with 0-2 R⁴ substituents; and

R⁴ is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

10 10. A compound according to claim 1, wherein:

R¹ and R², together with the nitrogen atom to which they are attached, form a heterocyclyl group selected from the group consisting of pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl,

15 wherein the heterocyclyl is substituted with 0-3 R⁴ substituents; and

R⁴ is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

20 11. A compound according to claim 1, wherein:

R¹ and R², together with the nitrogen atom to which they are attached, form a heterocyclyl group selected from the group consisting of piperidinyl, morpholinyl, and piperazinyl,

25 wherein the heterocyclyl is substituted with 0-3 R⁴ substituents; and

R⁴ is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

12. A compound according to claim 1, wherein:

30 R is H or NR¹R²;

R¹ and R², together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclenyl is substituted with 0-3 R⁴ substituents; and

- 5 R^4 is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

13. A compound according to claim 1, wherein:

R is H or NR¹R²;

- 10 R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclenyl is substituted with 0-2 R^4 substituents; and R^4 is selected from the group: halo, -CN, C₁₋₄ haloalkyl, 15 C₁₋₄ alkyl, phenyl, and benzyl.

14. A compound according to claim 1, wherein:

R is H or NR¹R²;

- R^1 and R^2 , together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group selected from the group consisting of: 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, 1,2,3,4- tetrahydrohydropyridine, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridine, 1,4,5,6- 25 tetrahydropyrimidine, wherein the heterocyclenyl is substituted with 0-2 R^4 substituents; and R^4 is selected from the group: halo, -CN, C₁₋₄ haloalkyl, C₁₋₄ alkyl, phenyl, and benzyl.

- 30 15. A compound according to claim 1, wherein:

R^4 is selected from the group: C₁₋₄ haloalkyl, C₁₋₄ alkyl, and benzyl.

16. A compound according to claim 1, wherein:

5 R^4 is C₁₋₄ alkyl.

17. A compound according to claim 1, wherein:

R^4 is methyl.

10 18. A compound according to claim 1, wherein:

R is NR¹R²; and

R¹ and R², together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclcyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclcyl

15 is substituted with a R^4 substituent.

19. A compound according to claim 1, wherein:

R is NR¹R²; and

R¹ and R², together with the nitrogen atom to which they are attached, form a 4-8 membered heterocyclenyl group containing an additional 0-1 N, S, or O atom, wherein the heterocyclenyl is substituted with a R^4 substituent.

20. A compound according to claim 1, wherein:

25 3-(2,4-dimethylthiazol-5-yl)-5- (carbamoylamino)indeno[1,2-c]pyrazol-4-one;

3-(2,4-dimethylthiazol-5-yl)-5-(morpholinocarbamoylamino)indeno[1,2-c]pyrazol-4-one;

30 3-(2,4-dimethylthiazol-5-yl)-5-((1-methyl-1-phenylamino)carbamoylamino)indeno[1,2-c]pyrazol-4-one;

3-(2,4-dimethylthiazol-5-yl)-5-((2,6-dimethylpiperidino)carbamoylamino)indeno[1,2-c]pyrazol-4-one; and

35 3-(2,4-dimethylthiazol-5-yl)-5-((4-methylpiperazino)carbamoylamino)indeno[1,2-c]pyrazol-4-one;

5 or stereoisomers thereof, N-Oxides thereof, pharmaceutically acceptable salts thereof, and prodrugs thereof.

21. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier and a therapeutically
10 effective amount of a compound of claim 1.

22. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier, a compound according to claim 1 or a pharmaceutically acceptable salt or prodrug
15 form thereof, and a cytostatic or cytotoxic agent.

23. A method of treating a cell proliferative disease associated with CDK activity in a patient in need thereof, comprising administering to said patient a
20 pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, wherein the proliferative diseases is selected from the group consisting of: Alzheimer's disease, viral infections, auto-immune diseases, fungal disease, cancer,
25 psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis, neurodegenerative disorders and post-surgical stenosis and restenosis.

30 24. A method of treating cancer associated with CDK activity in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof,
35 wherein the cancer is selected from the group consisting of: carcinoma such as bladder, breast, colon, kidney, liver,

5 lung, including small cell lung cancer, esophagus, gall-
bladder, ovary, pancreas, stomach, cervix, thyroid,
prostate, and skin, including squamous cell carcinoma;
hematopoietic tumors of lymphoid lineage, including
leukemia, acute lymphocytic leukemia, acute lymphoblastic
10 leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's
lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and
Burkett's lymphoma; hematopoietic tumors of myeloid lineage,
including acute and chronic myelogenous leukemias,
myelodysplastic syndrome and promyelocytic leukemia; tumors
15 of mesenchymal origin, including fibrosarcoma and
rhabdomyosarcoma; tumors of the central and peripheral
nervous system, including astrocytoma, neuroblastoma, glioma
and schwannomas; other tumors, including melanoma, seminoma,
teratocarcinoma, osteosarcoma, xeroderma pigmentosum,
20 keratocanthoma, thyroid follicular cancer and Kaposi's
sarcoma.

25. A method of treating a disease associated with
apoptosis in a patient in need thereof, comprising
25 administering to said patient a pharmaceutically effective
amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof,
wherein the disease associated with apoptosis is selected
from the group consisting of: cancer, viral infections,
30 autoimmune diseases and neurodegenerative disorder.

26. A method of inhibiting tumor angiogenesis and
metastasis in a patient in need thereof, comprising
administering to said patient a pharmaceutically effective
35 amount of a compound according to claim 1, or a
pharmaceutically acceptable salt or prodrug form thereof.

5

27. A method of modulating the level of cellular RNA and DNA synthesis in a patient in need thereof, comprising administering to said patient a CDK inhibitory effective amount of a compound according to claim 1, or a
10 pharmaceutically acceptable salt or prodrug form thereof.

28. A method of treating viral infections in a patient in need thereof, comprising administering to said patient a CDK inhibitory effective amount of a compound according to claim
15 1, or a pharmaceutically acceptable salt or prodrug form thereof, wherein the viral infections is selected from the group consisting of HIV, hepatitis, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus.

20

29. A method of chemopreventing cancer in a patient, comprising administering to said patient in need thereof, a CDK inhibitory effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug
25 form thereof.

30

30. A method of inhibiting CDK activity comprising combining an effective amount of a compound according to claim 1, with a composition containing CDK.

31. A method of treating cancer associated with CDK activity in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1, or a
35 pharmaceutically acceptable salt or prodrug form thereof, in combination (administered together or sequentially) with

5 known anti-cancer treatments such as radiation therapy or
with cytostatic or cytotoxic agents, wherein such agents are
selected from the group consisting of: DNA interactive
agents, such as cisplatin or doxorubicin; topoisomerase II
inhibitors, such as etoposide; topoisomerase I inhibitors
10 such as CPT-11 or topotecan; tubulin interacting agents,
such as paclitaxel, docetaxel or the epothilones; hormonal
agents, such as tamoxifen; thymidilate synthase inhibitors,
such as 5-fluorouracil; and anti-metabolites, such as
methoxtrexate.

15

32. A method treating cell proliferative diseases
associated with CDK activity in a patient in need thereof,
comprising administering to said patient a pharmaceutically
effective amount of a compound according to claim 1, or a
20 pharmaceutically acceptable salt or prodrug form thereof, in
combination (administered together or sequentially) with
known anti-proliferating agents selected from the group
consisting of: , altretamine, busulfan, chlorambucil,
cyclophosphamide, ifosfamide, mechlorethamine, melphalan,
25 thiotepa, cladribine, fluorouracil, floxuridine,
gemcitabine, thioguanine, pentostatin, methotrexate, 6-
mercaptopurine, cytarabine, carmustine, lomustine,
streptozotocin, carboplatin, cisplatin, oxaliplatin,
ipropilatin, tetraplatin, lobaplatin, JM216, JM335,
30 fludarabine, aminoglutethimide, flutamide, goserelin,
leuprolide, megestrol acetate, cyproterone acetate,
tamoxifen, anastrozole, bicalutamide, dexamethasone,
diethylstilbestrol, prednisone, bleomycin, dactinomycin,
daunorubicin, doxorubicin, idarubicin, mitoxantrone,
35 losoxantrone, mitomycin-c, plicamycin, paclitaxel,
docetaxel, CPT-11, epothilones , topotecan, irinotecan, 9-

- 5 amino camptothecan, 9-nitro camptothecan, GS-211, etoposide, teniposide, vinblastine, vincristine, vinorelbine, procarbazine, asparaginase, pegaspargase, methotrexate, octreotide, estramustine, and hydroxyurea.
- 10 33. A method of inhibiting CDK1 activity, comprising administering to a patient in need thereof an effective CDK1 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
- 15 34. A method of inhibiting CDK2 activity, comprising administering to a patient in need thereof an effective CDK2 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
- 20 35. A method of inhibiting CDK3 activity, comprising administering to a patient in need thereof an effective CDK3 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
- 25 36. A method of inhibiting CDK4 activity, comprising administering to a patient in need thereof an effective CDK4 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
- 30 37. A method of inhibiting CDK5 activity, comprising administering to a patient in need thereof an effective CDK5 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.
- 35 38. A method of inhibiting CDK6 activity, comprising administering to a patient in need thereof an effective CDK6

5 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

39. A method of inhibiting CDK7 activity, comprising
administering to a patient in need thereof an effective CDK7
10 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

40. A method of inhibiting CDK8 activity, comprising
administering to a patient in need thereof, an effective CDK8
15 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

41. A method of inhibiting CDK9 activity, comprising
administering to a patient in need thereof an effective CDK9
20 inhibitory amount of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof.

42. A pharmaceutical kit for treating a cell proliferative
disease associated with CDK activity, said kit comprising a
25 plurality of separate containers, wherein at least one of said containers contains a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug form thereof, and at least another of said containers contains one or more compounds selected from the group consisting of cytostatic
30 or cytotoxic agents, such as for example, but not limited to, DNA interactive agents, such as carboplatin, cisplatin or doxorubicin; topoisomerase II inhibitors, such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan; tubulin interacting agents, such as paclitaxel,
35 taxane, docetaxel or the epothilones; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-

5 fluorouracil; and anti-metabolites, such as methotrexate,
and said containers optionally contain a pharmaceutical
carrier, which kit may be effectively utilized for carrying
out combination therapies according to the invention.

10 43. A method of treating a patient having a disorder
associated with excessive cell proliferation, comprising
administering to the patient a therapeutically effective
amount of a compound of claim 1, such that the excessive
cell proliferation in the patient is reduced.

15 44. An enhanced method of inhibiting CDK activity,
comprising administering to a patient in need thereof an
effective CDK inhibitory amount of a compound according to
claim 1, or a pharmaceutically acceptable salt or prodrug
20 form thereof.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/044174 A3

(51) International Patent Classification⁷: **C07D 417/04**,
A61K 31/427, A61P 35/00

(21) International Application Number: PCT/US01/45227

(22) International Filing Date:
30 November 2001 (30.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/251,213 1 December 2000 (01.12.2000) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB PHARMA COMPANY**
[US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **YUE, Eddy, W.**
[US/US]; 9 Alternus Drive, Landenberg, PA 19350-1357 (US).

(74) Agents: **PATEL, Rena et al.**; Bristol-Myers Squibb Company, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(88) Date of publication of the international search report:
23 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/044174 A3

(54) Title: 3-(2,4-DIMETHYLTHIAZOL-5-YL) INDENO[1,2-C]PYRAZOL-4-ONE DERIVATIVES AS CDK INHIBITORS



(1)

(57) Abstract: The present invention relates to 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-ones of formula (1) which are potent inhibitors of cyclin dependent kinases. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/45227

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D417/04 A61K31/427 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 54308 A (DU PONT PHARM CO) 28 October 1999 (1999-10-28) cited in the application claim 1; examples 206,229 ---	1-44
P, X	US 2001/027195 A1 (DIMEO SUSAN V ET AL) 4 October 2001 (2001-10-04) page 16, line 14 - line 27 page 59 -page 63 ---	1-44
E	WO 02 46182 A (SQUIBB BRISTOL MYERS CO ;CARINI DAVID J (US)) 13 June 2002 (2002-06-13) claim 1; example 29 -----	1-44

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

1 August 2002

Date of mailing of the international search report

08/08/2002

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/45227

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 23-41,43,44 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/45227

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9954308	A	28-10-1999	AU 3654899 A	08-11-1999
			BR 9909597 A	02-10-2001
			CA 2322204 A1	28-10-1999
			CN 1297442 T	30-05-2001
			EP 1071668 A1	31-01-2001
			JP 2002512230 T	23-04-2002
			WO 9954308 A1	28-10-1999
			US 6413957 B1	02-07-2002
			US 2001027195 A1	04-10-2001
US 2001027195	A1	04-10-2001	US 6413957 B1	02-07-2002
			AU 3654899 A	08-11-1999
			BR 9909597 A	02-10-2001
			CA 2322204 A1	28-10-1999
			CN 1297442 T	30-05-2001
			EP 1071668 A1	31-01-2001
			JP 2002512230 T	23-04-2002
			WO 9954308 A1	28-10-1999
WO 0246182	A	13-06-2002	WO 0246182 A1	13-06-2002
			US 2002091127 A1	11-07-2002

1